Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Bicalutamide(Casodex)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 727Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 9Casodex

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Casodex

    Bicalutamide

    arrow
    Pharma Contract Manufacturing
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    Pharma Contract Manufacturing
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 172

    2019 Revenue in Millions : 200

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 143

    2020 Revenue in Millions : 172

    Growth (%) : -17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 78

    2021 Revenue in Millions : 143

    Growth (%) : -45

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 320

    2014 Revenue in Millions : 267

    Growth (%) : -17%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 215

    2016 Revenue in Millions : 247

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2014 Revenue in Millions : -14.90%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 201

    2017 Revenue in Millions : 215

    Growth (%) : -7%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 247

    2015 Revenue in Millions : 267

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Casodex

    Bicalutamide

    arrow
    DCAT Week
    Not Confirmed

    Brand Name : Casodex

    United Kingdom
    arrow
    DCAT Week
    Not Confirmed

    AstraZeneca

    Bicalutamide

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 200

    2018 Revenue in Millions : 201

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.